A lack of comprehension among some researchers about how to use ClinicalTrials.gov may be hindering public access to trial information and holding up drug study results, an investigation by The Scientist finds.
The biotech company Verve Therapeutics launched the study with the aim of using base editing to treat a genetic condition that causes high cholesterol and increases a person's risk of developing cardiovascular disease.
The shift is likely to add to an ongoing shortage of primates used in labs, which could slow progress in future COVID-19 vaccine development and other areas.
The device can chill nerves as small as a few millimeters across, but more testing and modifications are necessary before it could relieve pain in humans.